16 results about "Fibrotic lesion" patented technology

The invention relates to an application of a JAK inhibitor in preparation of a medicine for treating chronic kidney diseases, in particular to a compound 2-{N-[4-(4-methyl) piperazine] phenyl} amino-5, 6-dihydro-7-[3-(N-tert-butyl) sulfonamido] phenyl-pyrrolo [2, 3-d] pyrimidine or pharmaceutically acceptable salt thereof, and a preparation method of the compound 2-{N-[4-(4-methyl) piperazine] phenyl} amino-5, 6-dihydro-7-[3-(N-tertiary butyl) sulfonamido] phenyl-pyrrolo [2, 3-d] pyrimidine. The invention also relates to application of a pharmaceutical composition containing the compound in preparation of medicines for treating chronic kidney diseases. The compound has good treatment activity on chronic kidney diseases caused by various reasons, can remarkably reduce the inflammatory factor level of kidney tissue, further reduces kidney injury and fibrosis lesion degree, is high in safety, is expected to become a new medicine for treating the chronic kidney diseases, and has wide clinical application prospects.

The invention relates to the technical field of medical auxiliary diagnosis, and discloses a hypospadias penis curvature measuring method based on physical simulation inversion. The invention aims to solve the technical pain point that the penile erection curvature and the internal fibrosis focus distribution are difficult to quantify noninvasively and accurately before the operation in the existing hypospadias diagnosis and treatment. According to the method, a standard white mold containing fine anatomical partitions is constructed, personalized geometric mapping is realized by using a static look-around image, and constraint physical parameter inversion is performed in combination with a multi-attitude dynamic stress image, so that the digital twin with real biomechanical properties is reconstructed in a virtual environment. According to the method, the erection bending form can be accurately predicted in the non-erection state, the mechanical property abnormal area range is positioned, operation planning is assisted, experience medical treatment is spanned to accurate digital medical treatment, and the wound diagnosis and treatment and operation risks are remarkably reduced.

The present invention discloses a fibrosis detection method based on two-photon fluorescence lifetime microscopy and second harmonic imaging. The method comprises collecting two-photon fluorescence signals and second harmonic signals through a laser scanning microscope; generating and displaying fluorescence lifetime images, second harmonic images and image parameters through an imaging processing terminal according to the two-photon fluorescence signals and second harmonic signals, wherein the image parameters comprise fluorescence lifetime values ​​and the ellipticity ratio of the second harmonic image, and the fluorescence lifetime values ​​and the ellipticity ratio jointly characterize whether fibrosis lesions occur. The present invention adopts two-photon fluorescence lifetime microscopy technology to generate fluorescence lifetime images and fluorescence lifetime values ​​of biological tissues, and adopts second harmonic imaging technology to generate second harmonic images and ellipticity ratios, so that the experimenter can determine whether fibrosis lesions occur in biological tissues by comparing and analyzing the fluorescence lifetime images, second harmonic images, fluorescence lifetime values ​​and ellipticity ratios, thereby improving the accuracy of fibrosis lesion detection.

The application discloses an integrin-targeting peptide-collagenase drug combination and a drug composition constructed by the integrin-targeting peptide-collagenase drug combination. The drug combination can effectively block mechanical signals and biochemical signals mediating fibrosis, efficiently inhibit fibroblast activation, reduce the secretion of extracellular matrix proteins, and reshape the fibrotic microenvironment. Efficient reduction of fibrosis can promote the penetration of subsequent therapeutic drugs, and has a cascade penetration effect. The constructed drug composition can synergistically deliver integrin-targeting peptides and collagenase, and after release, the integrin-targeting peptides and collagenase can synergistically act in the form of free molecules in fibrotic lesions, thereby providing a new strategy for efficient delivery of fibrosis treatment drugs.

Provided is the use of an effective amount of alpha-enolase (enolase-1, ENO-1) antagonist in manufacturing a medicament for treating a fibrotic disease. ENO-1 antagonist significantly attenuated body weight loss and lung weight gain as well as the fibrosis lesion and collagen deposition in lungs. Also, ENO-1 antagonist significantly reduced cell migration and secretion of collagen and TGF-β in primary mouse lung myofibroblasts.

An ultrasound diagnostic apparatus includes an ultrasound transmission and reception unit that transmits and receives ultrasound waves to and from a subject and that generates a reception signal, an ultrasound information generation unit that generates a plurality of types of ultrasound information based on the reception signal, a detection and measurement unit that detects and measures a lesion based on the plurality of types of ultrasound information, and a lesion / risk information analysis unit that analyzes a state of the lesion based on a measurement result obtained by the detection and measurement unit. The detection and measurement unit includes at least one of a set of a tumorous lesion detection unit and a tumorous lesion measurement unit, a set of a fibrotic lesion detection unit and a fibrotic lesion measurement unit, a set of a calcified lesion detection unit and a calcified lesion measurement unit, or a set of a fatty liver detection unit and a fatty liver measurement unit.

The application belongs to the technical field of reversing liver fibrosis, and particularly relates to self-assembled nanoparticles for reversing liver fibrosis and a preparation method and application thereof. The nanoparticles comprise N-acetylmannosamine and 2-(2-propylpyridine-4-yl)-4-(p-tolyl)thiazole. The preparation method comprises the following steps: S1, self-assembly reaction: under stirring, an organic phase solution of 2-(2-propylpyridine-4-yl)-4-(p-tolyl)thiazole is added into an aqueous phase solution of N-acetylmannosamine, the mixed emulsion is continuously stirred, and then ultrasonic treatment is performed on the mixed emulsion to complete self-assembly; and S2, purification: the reaction solution after S1 is allowed to stand, centrifugation is performed to discard the supernatant, and then a washing solution is added into the centrifugal tube to resuspend the centrifugation, and the purified self-assembled nanoparticles are obtained after centrifugation. The application forms a stable nanostructure through intermolecular self-assembly of ManNAC and Fatostatin, realizes efficient enrichment and accurate release at a fibrotic lesion in the liver, and reverses the liver fibrosis process through synergistic regulation of a lipid metabolism axis.

The invention provides an application of dihydroberberine in preparation of a medicine for treating diabetic nephropathy. The application finds that dihydroberberine can obviously relieve kidney inflammation and fibrosis lesion in diabetic nephropathy and has an obvious protection effect on renal tubular epithelial cell injury induced by high glucose and high fat, and the bioavailability is obviously improved compared with berberine.

An ultrasound diagnostic apparatus includes an ultrasound transmission and reception unit that transmits and receives ultrasound waves to and from a subject and that generates a reception signal, an ultrasound information generation unit that generates a plurality of types of ultrasound information based on the reception signal, a detection and measurement unit that detects and measures a lesion based on the plurality of types of ultrasound information, and a lesion / risk information analysis unit that analyzes a state of the lesion based on a measurement result obtained by the detection and measurement unit. The detection and measurement unit includes at least one of a set of a tumorous lesion detection unit and a tumorous lesion measurement unit, a set of a fibrotic lesion detection unit and a fibrotic lesion measurement unit, a set of a calcified lesion detection unit and a calcified lesion measurement unit, or a set of a fatty liver detection unit and a fatty liver measurement unit.

This invention belongs to the field of biomedical technology and provides an application of a ferroptosis inhibitor in the treatment of hepatitis. This invention reveals that a GRIM-19 gene defect specifically induces ferroptosis in hepatocytes, rather than other cell death mechanisms such as apoptosis, necrosis, or autophagy. This invention provides a ferroptosis inhibitor with Ferrostatin-1 as the active ingredient, solving the technical problem of insufficient intervention against the ferroptosis mechanism in existing hepatitis treatments. This inhibitor can significantly increase the expression level of GPX4 in liver tissue, effectively clear lipid peroxides, a core toxic product in the ferroptosis process, and block the ferroptosis process; in addition, it can significantly inhibit the activation of the NLRP3 inflammasome and reduce the expression of downstream inflammatory factors, thereby alleviating inflammatory cell infiltration and fibrotic lesions in the liver. This invention is applicable to the treatment of GRIM-19 deficiency-related chronic hepatitis, providing a new strategy for targeted therapy of liver diseases.

Handheld intraoral device to objectively measure mucosal stiffness in OSMF and fibrotic lesions

The invention relates to an application of Kp1 (at) HCeO2 (at) SAM in preparation of drugs for treating or improving inflammatory bowel diseases, and the Kp1 (at) HCeO2 (at) SAM is prepared by embedding KP1-loaded HCeO2 composite nanoparticles into SAM. The invention further provides the Kp1 (at) HCeO2 (at) SAM for treating or improving the inflammatory bowel disease and a preparation method of the Kp1 (at) HCeO2 (at) SAM. According to the invention, the oral KP1 (at) HCeO2 (at) SAM composite microspheres are constructed, so that the acute inflammatory response of IBD is coordinated and intervened, and the chronic fibrosis process is reversed. In a DSS-induced mouse colitis model, the platform shows a staged curative effect: in an acute inflammation stage, HCeO2 efficiently clears active oxygen, promotes macrophage to be converted into M2 anti-inflammatory phenotype and reduces inflammatory factor expression, so that intestinal barrier function recovery is promoted; in the chronic fibrosis period, the sustained-release KP1 oligopeptide can inhibit a TGF-beta / Smad pathway in a targeted mode, myofibroblast activation and collagen deposition are remarkably inhibited, and therefore intestinal fibrosis lesion is reversed. Therefore, the composite microsphere disclosed by the invention, as a novel oral preparation for treating IBD, shows a wide clinical application prospect.

The invention discloses a long-acting stem cell as well as a preparation method and application thereof. The long-acting stem cell is obtained by introducing an exogenous polypeptide and connecting a stem cell synergist to the surface of the stem cell by utilizing a receptor-ligand recognition effect, the stem cell synergist is a nano-liposome; the long-acting stem cell has high survival efficiency and strong differentiation and proliferation capacity in a disease microenvironment, can effectively load a drug for improving the activity of the stem cell on a cell membrane, and realizes improvement of the in-vivo repair activity of the stem cell drug and enhancement of the survival ability of the stem cell on the premise of maintaining the integrity of the membrane structure of the stem cell. And the preparation method is simple to operate, is convenient and practical, and has a great prospect in practical application, and can be used for treating different injury-related diseases such as fibrosis lesions of liver, lung, pancreas and the like.

The present invention relates to the use of compositions comprising specific exosomes secreted by umbilical cord blood mononuclear cells (UCBMNCs) in the prevention and treatment of fibrotic disorders such as fibrotic skin and lung injuries. The exosome compositions of the invention present activity in skin fibrosis and in lung diseases. Moreover, these compositions are also effective in reverting or preventing disease-associated parameters, such of lung diseases, proving its action against respiratory disorders with an inflammatory component, particularly when mediated by macrophages and / or T-cells. Therefore, the present invention lays in the technical domain of pharmaceuticals, medicine, cosmetics, dermo-cosmetics, research and development in cellular biology and appliances thereof.

The invention relates to a gel composition containing pirfenidone, which is advantageous over other cutaneously administered pharmaceutical forms known in the prior art and which can be used in treatment for the restoration of tissues with fibrotic lesions and for the prevention of fibrotic lesions.

The invention discloses application of an integrin targeting peptide-collagenase medicine composition and a medicine composition constructed by the integrin targeting peptide-collagenase medicine composition. The pharmaceutical composition can effectively block mechanical signals and biochemical signals mediating fibrosis, efficiently inhibit fibroblast activation, reduce secretion of extracellular matrix protein and remodel a fibrosis microenvironment. The fibrosis can be efficiently relieved, the permeation of subsequent treatment drugs can be promoted, and the cascade permeation promotion effect is achieved. The constructed pharmaceutical composition can synergistically deliver integrin targeting peptide and collagenase, and after being released, the integrin targeting peptide and collagenase play a synergistic role in fibrosis lesions in a free molecule form, and a new strategy is provided for efficient delivery of fibrosis treatment drugs.